Overview

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Status:
NOT_YET_RECRUITING

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

Phase 3/4 open label, randomized two cohort study (2 arms in each cohort). It is hypothesized that for people with a histologically or cytologically confirmed diagnosis of malignancy, the higher dose immunotherapy (every 6 weeks Pembrolizumab 400mg dose and every 4 weeks Nivolumab 480mg dose) has more immune-related adverse events irAEs compared to lower dose (every 3 weeks Pembrolizumab 200mg dose and every 2 weeks Nivolumab 240mg dose).

Phase:

PHASE3

Details

Lead Sponsor:

University of Kansas Medical Center

Treatments:

Nivolumab
pembrolizumab